Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course ...

Geron Corporation's stock dropped 50% before its Q4 2024 earnings report, with Rytelo's revenue close to projections but new ...

Hello and welcome to the Geron fourth quarter and full year 2024 earnings call. All lines have been placed on mute to prevent ...

FOSTER CITY, Calif. (AP) — FOSTER CITY, Calif. (AP) — Geron Corp. (GERN) on Wednesday reported a loss of $25.4 million in its fourth quarter. The Foster City, California-based company said it had a ...

Shares of Geron Corp (NASDAQ: NASDAQ:GERN) plummeted 30% following the company's release of fourth-quarter earnings that failed to meet analyst expectations and its guidance that left investors ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that members of the management team are scheduled to p ...

The polycythemia vera market over the next few years is expected to substantially change and experience growth, as it will be dominated by two already approved products, Incyte/Novartis' JAKAFI ...

Geron (NASDAQ:GERN) stock plunged 30% after management reportedly indicated on the company's Q4 earnings call that sales of ...

By selling its China business to AstraZeneca, FibroGen can focus on developing a prostate cancer drug and potentially resuming development of roxadustat in another indication.

Angiochem licensed to Geron Corp. for $37 million upfront, a vectorised form of Paclitaxel (Angiopep-2 peptide conjugated to Paclitaxel) to treat brain tumours, and signed in February 2012 a deal ...